The dual role of glioma exosomal microRNAs: glioma eliminates tumor suppressor miR-1298-5p via exosomes to promote immunosuppressive effects of MDSCs.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
received:
06
09
2021
accepted:
20
04
2022
revised:
14
04
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Clear evidence shows that tumors could secrete microRNAs (miRNAs) via exosomes to modulate the tumor microenvironment (TME). However, the mechanisms sorting specific miRNAs into exosomes are still unclear. In order to study the biological function and characterization of exosomal miRNAs, we performed whole-transcriptome sequencing in 59 patients' whole-course cerebrospinal fluid (CSF) small extracellular vesicles (sEV) and matched glioma tissue samples. The results demonstrate that miRNAs could be divided into exosome-enriched miRNAs (ExomiRNAs) and intracellular-retained miRNAs (CLmiRNAs), and exosome-enriched miRNAs generally play a dual role. Among them, miR-1298-5p was enriched in CSF exosomes and suppressed glioma progression in vitro and vivo experiments. Interestingly, exosomal miR-1298-5p could promote the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) to facilitate glioma. Therefore, we found miR-1298-5p had different effects on glioma cells and MDSCs. Mechanically, downstream signaling pathway analyses showed that miR-1298-5p plays distinct roles in glioma cells and MDSCs via targeting SETD7 and MSH2, respectively. Moreover, reverse verification was performed on the intracellular-retained miRNA miR-9-5p. Thus, we confirmed that tumor-suppressive miRNAs in glioma cells could be eliminated through exosomes and target tumor-associated immune cells to induce tumor-promoting phenotypes. Glioma could get double benefit from it. These findings uncover the mechanisms that glioma selectively sorts miRNAs into exosomes and modulates tumor immunity.
Identifiants
pubmed: 35501306
doi: 10.1038/s41419-022-04872-z
pii: 10.1038/s41419-022-04872-z
pmc: PMC9061735
doi:
Substances chimiques
MIRN1298 microRNA, human
0
MicroRNAs
0
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
SETD7 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
426Informations de copyright
© 2022. The Author(s).
Références
Cancer Res. 2020 Jul 1;80(13):2874-2888
pubmed: 32265223
EBioMedicine. 2018 Nov;37:134-143
pubmed: 30361067
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Signal Transduct Target Ther. 2021 Feb 18;6(1):69
pubmed: 33597502
Oncotarget. 2016 Dec 6;7(49):80521-80542
pubmed: 27602954
Mol Oncol. 2018 Nov;12(11):1949-1964
pubmed: 30171794
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Sci Adv. 2020 Dec 16;6(51):
pubmed: 33328224
Cell Death Dis. 2019 Jan 15;10(2):33
pubmed: 30674889
Oncogene. 2020 Jan;39(2):428-442
pubmed: 31485019
Cell Rep. 2016 Oct 11;17(3):799-808
pubmed: 27732855
PLoS One. 2016 May 16;11(5):e0154939
pubmed: 27183310
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Front Oncol. 2021 Apr 01;11:631703
pubmed: 33869017
Oncogene. 2018 Aug;37(31):4239-4259
pubmed: 29713056
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452
pubmed: 28031556
Int J Cancer. 2019 Jun 15;144(12):3111-3126
pubmed: 30536597
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
Nucleic Acids Res. 2017 Jan 4;45(D1):D104-D114
pubmed: 28053162
Int J Mol Med. 2020 May;45(5):1616-1626
pubmed: 32323737
Nat Rev Cancer. 2020 Jan;20(1):12-25
pubmed: 31806885
J Extracell Vesicles. 2015 Jun 19;4:27522
pubmed: 26095380
Nat Commun. 2017 Apr 10;8:15016
pubmed: 28393839
Elife. 2016 Aug 25;5:
pubmed: 27559612
Neuroimage Clin. 2014 Aug 15;6:9-19
pubmed: 25379412
Cancer Res. 2016 Aug 1;76(15):4383-93
pubmed: 27261510
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
Nat Commun. 2017 Feb 17;8:14448
pubmed: 28211508
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
J Clin Invest. 2020 Jan 2;130(1):404-421
pubmed: 31593555